HealthcareServices

Persistent Epithelial Defect Management Industry Growth Insights: Revenue Forecast to 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the persistent epithelial defect management market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Persistent Epithelial Defect Management Market?

The market for managing persistent epithelial defects has experienced swift growth recently. This market is anticipated to expand from $9.26 billion in 2025 to $10.82 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.9%. Historically, this growth was influenced by factors such as a lack of awareness regarding persistent epithelial defects, dependence on standard lubricating eye drops, sluggish integration of autologous serum therapy, insufficient availability of corneal specialists, and inconsistent patient follow-up and oversight.

The persistent epithelial defect management market is poised for significant expansion in the coming years. It is projected to attain a size of $19.94 billion by 2030, advancing at a compound annual growth rate (CAGR) of 16.5%. This anticipated growth during the forecast period is fueled by advancements in stem cell and biologic therapies, the rising adoption of amniotic membrane transplantation, an increasing preference for bandage contact lenses, growing awareness surrounding early corneal defect management, and the expansion of hospital and specialized eye care centers. Significant trends observed within the forecast period encompass the increasing integration of AI-powered diagnostic and imaging tools, an expanded application of biologics and stem cell therapies, the adoption of cloud-based patient monitoring systems, the development of IoT-enabled eye care devices, and innovations in the automated manufacturing processes for ocular therapeutics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21256&type=smp

What Drivers Are Supporting Technological Adoption In The Persistent Epithelial Defect Management Market?

The persistent epithelial defect management market is anticipated to expand due to the growing occurrence of eye disorders. These disorders encompass various medical conditions impacting the eyes’ structure, function, or overall health, often resulting in impaired vision, discomfort, or even blindness. Factors contributing to the rise in eye disorders include an aging global population, extended periods of screen use, and shifts in environmental conditions. Effective management of persistent epithelial defects is crucial for addressing eye disorders, as it aids in healing, reduces inflammation, and guards against potential issues like infections or scarring. As an illustration, a report in December 2024 from the World Health Organization, an intergovernmental organization based in Switzerland, indicated that the total pooled prevalence of childhood myopia reached 5.23% in 2023, with females exhibiting a notably higher rate of 4.90% compared to males at 3.94%. Consequently, the expanding incidence of eye disorders is a key factor propelling the persistent epithelial defect management market’s growth.

What Segment Types Are Examined In The Persistent Epithelial Defect Management Market?

The persistent epithelial defect management market covered in this report is segmented –

1) By Disease Type: Epithelial Or Limbal, Inflammatory Disease, Neurotrophic Disease, Other Disease Types

2) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Hospitals

3) By End User: Hospitals And Specialty Eye Clinics, Physician Offices, Ophthalmology Specialty Centers, Other End Users

Subsegments:

1) By Epithelial Or Limbal: Limbal Stem Cell Deficiency (LSCD), Limbal Transplantation, Conjunctival Transplantation

2) By Inflammatory Disease: Dry Eye Syndrome, Allergic Conjunctivitis, Uveitis

3) By Neurotrophic Disease: Herpes Simplex Virus (HSV) Keratitis, Corneal Nerve Damage Associated Keratopathy, Neurotrophic Keratopathy

4) By Other Disease Types: Chemical Burns, Trauma-Induced Defects, Congenital Corneal Opacities

Which Trends Are Shaping Activity Within The Persistent Epithelial Defect Management Market?

Major companies in the persistent epithelial defect management market are concentrating on developing innovative therapies, such as secretome therapy, to accelerate healing and improve treatment outcomes for persistent epithelial defects. Secretome therapy involves using bioactive molecules secreted by cells, including proteins, lipids, and extracellular vesicles, to promote tissue repair, modulate immune responses, and treat various diseases. For instance, in April 2023, Kala Pharmaceuticals Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) Fast Track Designation for KPI-012, which is a human MSC-S therapy intended for persistent corneal epithelial defect. The drug’s multifactorial mechanism of action aims to address all underlying causes of persistent epithelial defect management by fostering corneal healing through bioactive molecules like growth factors, protease inhibitors, and neurotrophic factors.

Who Are The Top-Performing Companies In The Persistent Epithelial Defect Management Market In Recent Years?

Major companies operating in the persistent epithelial defect management market are AbbVie Inc., Novartis AG, Johnson & Johnson Vision, RegeneRx Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Vision Care, Santen Pharmaceutical Co. Ltd., Recordati Rare Diseases Inc., Dompé Farmaceutici S.p.A., TissueTech Inc., Ocular Therapeutix Inc., Amber Ophthalmics Inc., Noveome Biotherapeutics Inc., OcuNexus Therapeutics Inc., Lux Bio Inc., Eyenovia Inc., Kala Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., EyePoint Pharmaceuticals Inc., Aldeyra Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/persistent-epithelial-defect-management-global-market-report

Which Region Currently Holds The Largest Share Of The Persistent Epithelial Defect Management Market?

North America was the largest region in the persistent epithelial defect management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the persistent epithelial defect management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Persistent Epithelial Defect Management Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21256&type=smp

Browse Through More Reports Similar to the Global Persistent Epithelial Defect Management Market 2026, By The Business Research Company

Cell Regeneration Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-regeneration-medicine-global-market-report

Defect Detection Market Report 2026

https://www.thebusinessresearchcompany.com/report/defect-detection-global-market-report

Leak Detection And Repair Market 2026

https://www.thebusinessresearchcompany.com/report/leak-detection-and-repair-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795